Connor, Clark & Lunn Investment Management Ltd. Eton Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Eton Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 222,083 shares of ETON stock, worth $4.12 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
222,083
Previous 232,532
4.49%
Holding current value
$4.12 Million
Previous $3.02 Million
4.84%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding ETON
# of Institutions
90Shares Held
15MCall Options Held
242KPut Options Held
11.8K-
Opaleye Management Inc. Boston, MA2.86MShares$53.1 Million9.75% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.03MShares$37.7 Million2.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.31MShares$24.4 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.18MShares$21.8 Million0.73% of portfolio
-
Geode Capital Management, LLC Boston, MA593KShares$11 Million0.0% of portfolio
About Eton Pharmaceuticals, Inc.
- Ticker ETON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,297,000
- Market Cap $470M
- Description
- Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for th...